An ‘atlas’ of the brain spurs discovery of new cells that could provide map for stroke, Alzheimer’s treatmentsnews2022-01-31T18:23:27+00:00January 31st, 2022|FierceBiotech|
Leo Pharma picks Christophe Bourdon as CEO after one-year stint at failed Danish meme stock Orphazymenews2022-01-31T17:14:08+00:00January 31st, 2022|FierceBiotech|
Leo Pharma picks Bourdon as CEO after one-year stint at failed Danish meme stock Orphazymenews2022-01-31T17:14:08+00:00January 31st, 2022|FierceBiotech|
Led by Nanopore and Exscientia, UK startups snag half of Europe’s biotech VC funding in record-setting 2021news2022-01-31T15:14:53+00:00January 31st, 2022|FierceBiotech|
Gamida Cell readies stem cell transplant therapy for FDA submission but seeks strategic partners amid staffing cutsnews2022-01-31T14:33:56+00:00January 31st, 2022|FierceBiotech|
Madrigal’s NASH prospect clears first phase 3 test, raising hopes it can magic up positive pivotal efficacy data news2022-01-31T13:54:07+00:00January 31st, 2022|FierceBiotech|
Pfizer ends $3B drug dream despite phase 2b success, leaving Regeneron with a clear run at cardiovascular marketnews2022-01-31T13:04:43+00:00January 31st, 2022|FierceBiotech|
UPDATE: Kaleido confirms layoffs, halts planned phase 2 and appears to have ended COVID-19 programnews2022-01-28T19:37:35+00:00January 28th, 2022|FierceBiotech|
Charles River Labs deals with SAMDI Tech to boost discovery businessnews2022-01-28T17:58:21+00:00January 28th, 2022|FierceBiotech|
Yet another delay at Amryt as EMA calls in experts to inform review of rare disease drug news2022-01-28T13:20:00+00:00January 28th, 2022|FierceBiotech|
